Zhuang Yu

7PUBLICATIONS
21CO-AUTHORS
Molecular targetsInnate immunityCancer therapy (excl. chemotherapy and radiation therapy)AvionicsPredictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (7)

|Nov 28, 2024
YY1 downregulation underlies therapeutic response to molecular targeted agents.

Shichao Zhou, Jingyu Zang, Mei-Chun Cai

|Apr 04, 2024
Gut microbiome affects the response to immunotherapy in non-small cell lung cancer.

Shengnan Ren, Lingxin Feng, Haoran Liu

|Oct 07, 2022
Toripalimab Plus Chemotherapy for Patients With Treatment-Naive Advanced Non-Small-Cell Lung Cancer: A Multicenter Randomized Phase III Trial (CHOICE-01).

Zhijie Wang, Lin Wu, Baolan Li

|Sep 28, 2022
Transient targeting of BIM-dependent adaptive MCL1 preservation enhances tumor response to molecular therapeutics in non-small cell lung cancer.

Kaixuan Shi, Haijiao Lu, Zhenfeng Zhang

|May 17, 2022
AENEAS: A Randomized Phase III Trial of Aumolertinib Versus Gefitinib as First-Line Therapy for Locally Advanced or MetastaticNon-Small-Cell Lung Cancer With EGFR Exon 19 Deletion or L858R Mutations.

Shun Lu, Xiaorong Dong, Hong Jian

|Dec 16, 2020
Subgroup analysis by prior anti-VEGF or anti-EGFR target therapy in FRESCO, a randomized, double-blind, Phase III trial.

Ruihua Xu, Shukui Qin, Weijian Guo

Pageof 2

Frequent Collaborators

2 joint publications

Guanglei Zhuang

2 joint publications

Xiaojing Zhao

2 joint publications

Qiming Wang

1 joint publications

Li Tan